Early phase clinical trials
Early phase studies are often designed and implemented without substantive statistical input. The 3+3 maximum tolerated dose finding design being a classic example. This group aims to improve statistical aspects of early phase studies by bridging the gap between clinical trialists using traditional designs and modern statistical methodologists with many improvements to offer.
We are interested in reaching a consensus within the statistical community of which modern methods should be regarded as standard, and communicating these methods to a wider audience through training and education to increase their use in real-life trials.
Collaborative research enables us to consolidate our knowledge and share expertise. Our research section seeks to undertake collaborative working to promote high quality research by tackling discipline specific issues.
If you would like to be part of a research section or wish to find out more please email the NIHR Statistics Group.
The Institute of Cancer Research
Cambridge Clinical Trials Unit
Section committee members
University of Cardiff
University of Lancaster
University College London
Early phase clinical trials Publications
BMC Medical Research Methodology, in press
British Journal of Cancer advance online publication 29 June 2017
Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose finding, such as the continual reassessment method